Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.
Since the discovery of the cannabinoid CB2 receptor in 1993, there has been a growing interest to clarify the importance of this G-protein coupled receptor (GPCR) for human physiology, and to investigate it as a possible target for current and future drug development. Several mutation studies have examined the receptor activation and structure of the receptor binding cavity. Additionally, 3D models for the CB2 receptor have been constructed to aid in perceiving important ligand-receptor interactions. In recent years, many research groups have succeeded in synthesizing new CB2 selective ligands. This review focuses on (i) important features for ligand recognition and/or receptor activation at CB2, derived from mutation and modeling studies, and (ii) recent advances in the field of CB2 selective ligands.
Raitio
K H
KH
Department of Pharmaceutical Chemistry, University of Kuopio. P. O. Box 1627, 70211 Kuopio, Finland. Katri.Raitio@uku.fi
Salo
O M H
OM
Nevalainen
T
T
Poso
A
A
Järvinen
T
T
D000818:Animals; D002186:Cannabinoids / Q000737:chemistry / Q000378:metabolism*; D015195:Drug Design; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D009154:Mutation; D017433:Protein Structure, Secondary; D043885:Receptor, Cannabinoid, CB2 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism
D002186:Cannabinoids; D008024:Ligands; D043885:Receptor, Cannabinoid, CB2